Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CTD nuclear envelope phosphatase 1 (CTDNEP1) is a magnesium-dependent, noncanonical protein serine/threonine phosphatase within the DXDX(T/V) phosphatase family. It forms a membrane protein complex with NEP1R1, its regulatory subunit, to dephosphorylate lipin family proteins and thereby regulate lipid biosynthesis and ER membrane expansion. CTDNEP1 is essential for maintaining proper ER and nuclear envelope morphology; its loss or inactivation leads to excessive ER expansion. Mutations in CTDNEP1 are linked to aggressive childhood medulloblastoma and may play roles in neural development by modulating BMP signaling. The molecular structure of the CTDNEP1–NEP1R1 complex has recently been elucidated, revealing mechanisms of substrate specificity, allosteric regulation, and the basis for cancer-associated mutations[1][2][3][4].
Drugs targeting this molecule would likely act by modulating its phosphatase activity or the CTDNEP1–NEP1R1 complex's ability to dephosphorylate lipin, thereby affecting ER biogenesis and lipid synthesis[1][2][3]. However, no clinically available drugs with this exact mechanism are listed in the present literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-terminal domain nuclear envelope phosphatase 1 (CTDNEP1).